Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
Research identifies a gene that may be linked to focal cortical dysplasia, a common cause of drug-resistant epilepsy. New research has identified changes (mutations) in a gene called FOXJ3 that may be ...
Researchers from the RCSI University of Medicine and Health Sciences have developed a new 3D implant solution that helps heal spinal cord injuries. Their study, published in the journal Bioactive ...
Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...
A new gene editor may soon open the door to gene therapies for a wider array of diseases. Ask scientists what gene editing tool is most needed to advance gene therapy, and they'd probably describe a ...
Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results